When performed in a clinical setting by professionals, copper peptide injections can be safe
Injection site reactions (mild redness, transient swelling) are the most common, typically resolving within 24 hours
Some institutes and centers, moreover, only report extramural research or do not make explicit distinctions between intramural and extramural research, and provide limited contextual information that would help explain large differences in total or subgroup enrollment data in some years
No sedation, no suppression of REM, no morning grogginess
The pace of change varies
In the Phase II trial, 73% to 94% of participants reported side effects with retatrutide, especially at the higher doses of 8 mg and 12 mg once weekly